These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 25132263

  • 1. BRCA1-IRIS inactivation sensitizes ovarian tumors to cisplatin.
    Paul BT, Blanchard Z, Ridgway M, ElShamy WM.
    Oncogene; 2015 Jun 04; 34(23):3036-52. PubMed ID: 25132263
    [Abstract] [Full Text] [Related]

  • 2. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
    Blanchard Z, Paul BT, Craft B, ElShamy WM.
    Breast Cancer Res; 2015 Jan 13; 17(1):5. PubMed ID: 25583261
    [Abstract] [Full Text] [Related]

  • 3. BRCA1-IRIS overexpression promotes cisplatin resistance in ovarian cancer cells.
    Chock KL, Allison JM, Shimizu Y, ElShamy WM.
    Cancer Res; 2010 Nov 01; 70(21):8782-91. PubMed ID: 20940403
    [Abstract] [Full Text] [Related]

  • 4. T-Type Ca2+ Channel Inhibition Sensitizes Ovarian Cancer to Carboplatin.
    Dziegielewska B, Casarez EV, Yang WZ, Gray LS, Dziegielewski J, Slack-Davis JK.
    Mol Cancer Ther; 2016 Mar 01; 15(3):460-70. PubMed ID: 26832797
    [Abstract] [Full Text] [Related]

  • 5. miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition.
    Sun C, Li N, Yang Z, Zhou B, He Y, Weng D, Fang Y, Wu P, Chen P, Yang X, Ma D, Zhou J, Chen G.
    J Natl Cancer Inst; 2013 Nov 20; 105(22):1750-8. PubMed ID: 24168967
    [Abstract] [Full Text] [Related]

  • 6. Downregulation of ATG14 by EGR1-MIR152 sensitizes ovarian cancer cells to cisplatin-induced apoptosis by inhibiting cyto-protective autophagy.
    He J, Yu JJ, Xu Q, Wang L, Zheng JZ, Liu LZ, Jiang BH.
    Autophagy; 2015 Nov 20; 11(2):373-84. PubMed ID: 25650716
    [Abstract] [Full Text] [Related]

  • 7. JNK- and Akt-mediated Puma expression in the apoptosis of cisplatin-resistant ovarian cancer cells.
    Zhao Z, Wang J, Tang J, Liu X, Zhong Q, Wang F, Hu W, Yuan Z, Nie C, Wei Y.
    Biochem J; 2012 Jun 01; 444(2):291-301. PubMed ID: 22394200
    [Abstract] [Full Text] [Related]

  • 8. Preclinical Efficacy for AKT Targeting in Clear Cell Carcinoma of the Ovary.
    Sasano T, Mabuchi S, Kuroda H, Kawano M, Matsumoto Y, Takahashi R, Hisamatsu T, Sawada K, Hashimoto K, Isobe A, Testa JR, Kimura T.
    Mol Cancer Res; 2015 Apr 01; 13(4):795-806. PubMed ID: 25519148
    [Abstract] [Full Text] [Related]

  • 9. Sequential therapeutic targeting of ovarian Cancer harboring dysfunctional BRCA1.
    Baloch T, López-Ozuna VM, Wang Q, Matanis E, Kessous R, Kogan L, Yasmeen A, Gotlieb WH.
    BMC Cancer; 2019 Jan 10; 19(1):44. PubMed ID: 30630446
    [Abstract] [Full Text] [Related]

  • 10. Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells.
    Yue P, Zhang X, Paladino D, Sengupta B, Ahmad S, Holloway RW, Ingersoll SB, Turkson J.
    Oncogene; 2012 May 03; 31(18):2309-22. PubMed ID: 21909139
    [Abstract] [Full Text] [Related]

  • 11. BRCA1-associated epigenetic regulation of p73 mediates an effector pathway for chemosensitivity in ovarian carcinoma.
    Ibrahim N, He L, Leong CO, Xing D, Karlan BY, Swisher EM, Rueda BR, Orsulic S, Ellisen LW.
    Cancer Res; 2010 Sep 15; 70(18):7155-65. PubMed ID: 20807817
    [Abstract] [Full Text] [Related]

  • 12. ARHI (DIRAS3)-mediated autophagy-associated cell death enhances chemosensitivity to cisplatin in ovarian cancer cell lines and xenografts.
    Washington MN, Suh G, Orozco AF, Sutton MN, Yang H, Wang Y, Mao W, Millward S, Ornelas A, Atkinson N, Liao W, Bast RC, Lu Z.
    Cell Death Dis; 2015 Aug 06; 6(8):e1836. PubMed ID: 26247722
    [Abstract] [Full Text] [Related]

  • 13. 8‑bromo‑7‑methoxychrysin induces apoptosis by regulating Akt/FOXO3a pathway in cisplatin‑sensitive and resistant ovarian cancer cells.
    Ding Q, Chen Y, Zhang Q, Guo Y, Huang Z, Dai L, Cao S.
    Mol Med Rep; 2015 Oct 06; 12(4):5100-8. PubMed ID: 26151347
    [Abstract] [Full Text] [Related]

  • 14. [Influence of mifepristone on DNA repair genes and cisplatin sensitivity in human ovarian cancer drug-resistance cells].
    Liu GY, Qu QX, Mi RR, Qi J.
    Zhonghua Fu Chan Ke Za Zhi; 2008 Feb 06; 43(2):132-5. PubMed ID: 18683754
    [Abstract] [Full Text] [Related]

  • 15. Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner.
    Yan X, Fraser M, Qiu Q, Tsang BK.
    Gynecol Oncol; 2006 Aug 06; 102(2):348-55. PubMed ID: 16545436
    [Abstract] [Full Text] [Related]

  • 16. Aurora-A/SOX8/FOXK1 signaling axis promotes chemoresistance via suppression of cell senescence and induction of glucose metabolism in ovarian cancer organoids and cells.
    Sun H, Wang H, Wang X, Aoki Y, Wang X, Yang Y, Cheng X, Wang Z, Wang X.
    Theranostics; 2020 Aug 06; 10(15):6928-6945. PubMed ID: 32550913
    [Abstract] [Full Text] [Related]

  • 17. EZH2 participates in malignant biological behavior of epithelial ovarian cancer through regulating the expression of BRCA1.
    Li T, Cai J, Ding H, Xu L, Yang Q, Wang Z.
    Cancer Biol Ther; 2014 Mar 01; 15(3):271-8. PubMed ID: 24335192
    [Abstract] [Full Text] [Related]

  • 18. [Effects of Zengmian Yiliu Recipe combined cisplatin on the tumor inhibition rate in platinum-resistant ovarian cancer].
    Qi C, Zhang QH, Li JX.
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2012 Jun 01; 32(6):817-21. PubMed ID: 22978111
    [Abstract] [Full Text] [Related]

  • 19. FOXP1 functions as an oncogene in promoting cancer stem cell-like characteristics in ovarian cancer cells.
    Choi EJ, Seo EJ, Kim DK, Lee SI, Kwon YW, Jang IH, Kim KH, Suh DS, Kim JH.
    Oncotarget; 2016 Jan 19; 7(3):3506-19. PubMed ID: 26654944
    [Abstract] [Full Text] [Related]

  • 20. RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.
    Liu M, Qi Z, Liu B, Ren Y, Li H, Yang G, Zhang Q.
    Oncotarget; 2015 Sep 22; 6(28):25281-94. PubMed ID: 26325371
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.